Bottom line
Is ESCFX a good fund? The bottom line
ESCFX is the Class A share class of 1290 Essex Small Cap Growth Fund, an actively managed small-cap mutual fund from MFS.
Its expense ratio is 1.13% — about $113 a year on every $10,000 invested, more expensive than 63% of small-cap funds we track.
It returned +22.3% over one year (as of Dec 31, 2025, per its prospectus).
With $116 million in net assets and 102 holdings, its largest position is Kiniksa Pharmaceuticals International plc (2.6%) and the top 10 make up 21.6% of the portfolio.
This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.
What to watch
- Front-end sales load up to 5.5%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What ESCFX invests in
Seeks long-term growth of capital.
Under normal circumstances, the Fund invests at least 80% of its net assets, plus borrowings for investment purposes, in equity securities of small- and micro-capitalization companies (or other financial instruments that derive their value from the securities of such companies). For the Fund, a company is considered to be a small-capitalization company if, at the time of purchase, its market capitalization is less than or equal to the market capitalization of the largest company included within the Russell 2000 Growth Index. As of December 31, 2025, the market capitalizations of companies in the Russell 2000 Growth Index ranged from approximately $29.8 million to $37.6 billion. This capitalization range will change over time. The Funds investments include U.S. micro-cap companies, which, at the time of purchase, have capitalizations that place them among the smallest 5% of companies…
From the fund's prospectus (filed Feb 24, 2026).
ESCFX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| ESCFX | +22.3% | — | — |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What ESCFX costs
On a $10,000 investment, ESCFX's 1.13% expense ratio costs about $113 a year. The prospectus estimates $2,203 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
ESCFX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Kiniksa Pharmaceuticals International plc | 2.61% |
| 2 | Lincoln Educational Services Corp. | 2.53% |
| 3 | Leonardo DRS, Inc. | 2.39% |
| 4 | JPMorgan Prime Money Market Fund | 2.29% |
| 5 | Adaptive Biotechnologies Corp. | 2.23% |
| 6 | CECO Environmental Corp. | 2.08% |
| 7 | Invesco Govt And Agcy Lex | 1.90% |
| 8 | Graham Corp. | 1.88% |
| 9 | Argan, Inc. | 1.86% |
| 10 | Brainsway Ltd. | 1.82% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 21.6% of the fund. See all top 25 holdings and asset mix →